Repare Therapeutics Inc (RPTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Repare Therapeutics Inc (RPTX) has a cash flow conversion efficiency ratio of 0.023x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($2.65 Million) by net assets ($115.13 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Repare Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Repare Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Repare Therapeutics Inc carry for a breakdown of total debt and financial obligations.
Repare Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Repare Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Azerion Group N.V.
AS:AZRN
|
-0.328x |
|
TOPTEC Co. Ltd
KQ:108230
|
-0.065x |
|
Poh Kong Holdings Bhd
KLSE:5080
|
0.026x |
|
P2 Gold Inc
V:PGLD
|
-0.045x |
|
Daihan Pharmaceutical Co.Ltd
KQ:023910
|
0.032x |
|
Humanica Public Company Limited
BK:HUMAN
|
0.044x |
|
Safari Investments RSA Ltd
JSE:SAR
|
0.015x |
|
CEA Industries Inc.
NASDAQ:BNC
|
0.004x |
Annual Cash Flow Conversion Efficiency for Repare Therapeutics Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Repare Therapeutics Inc from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see Repare Therapeutics Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $151.13 Million | $-76.44 Million | -0.506x | +15.64% |
| 2023-12-31 | $212.08 Million | $-127.16 Million | -0.600x | -52146.58% |
| 2022-12-31 | $279.52 Million | $322.00K | 0.001x | +100.39% |
| 2021-12-31 | $288.42 Million | $-85.80 Million | -0.297x | -1302.41% |
| 2020-12-31 | $286.83 Million | $-6.08 Million | -0.021x | +89.66% |
| 2019-12-31 | $89.87 Million | $-18.43 Million | -0.205x | -136.38% |
| 2018-12-31 | $-22.38 Million | $-12.62 Million | 0.564x | -- |
About Repare Therapeutics Inc
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. It also develops camo… Read more